BostonGene and Exigent Genomic INsight Study for Advanced Cancers
This study, called the BEGIN Study, is looking at how well a special test called the BostonGene Tumor Portrait test works for people with advanced breast cancer, non-small cell lung cancer, melanoma, or sarcoma. This test looks closely at your tumor to find specific changes that might help doctors choose the best treatment for you. The study wants to see how often these helpful findings are discovered and how quickly the test results are available. It also aims to understand if these test results help patients join other clinical trials. The study plans to enroll 400 people and is currently observational, meaning it watches what happens without giving specific treatments.
- Study design
- This is an observational study with 400 participants, divided into four groups of 100 people each, based on their type of advanced cancer.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will measure outcomes like actionable findings and test turn-around time over a period of two years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
BostonGene and Exigent Genomic INsight Study
At a glance
Conditions
Where it's being run
7 sites across 7 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Frequency of actionable findings2 years
the frequency of actionable findings identified by a comprehensive (WES/RNA) sequencing platform (BostonGene Tumor Portrait) in advanced cancer patients. Actionable findings will include: genomic findings such as fusions, single nucleotide variants (SNVs), insertion/deletion alterations (indels), copy number alterations (CNAs), tumor mutational burden (TMB), microsatellite instability (MSI), frameshifts, rearrangements, gene expression levels, genome instability and loss of heterozygosity, cell counts in TME, disease molecular type, inherited pathogenic mutations, mutational signatures, and gene isoform expression.
- Test turn-around time2 years
the time from consent to biopsy (or archival tissue retrieval), time from receipt of biopsy to BostonGene Tumor Portrait testing results, and total time from consent to delivery of BostonGene Tumor Portrait testing resultsTumor Portrait testing